---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-099856"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T20:50:29.030461+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics provides pipeline update; SHINE interim shows 3-point ADAS-Cog benefit

## Summary
- Cash and equivalents $37.2M as of June 30, 2023; expected runway through Q3 2024.
- Total grant funding ~$171M; $81.8M remaining as of June 30, 2023.
- SHINE Phase 2 interim (n=24) showed 3-point ADAS-Cog-11 difference at Day 185 vs placebo.
- Topline data for SHINE (mild-moderate AD) and SHIMMER (DLB) expected mid-2024.
- Phase 2 START (early AD) enrolling; MAGNIFY (dry AMD) in development.

## SEC filing metadata
- accession: 0001104659-23-099856
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923099856/0001104659-23-099856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923099856/tm2325877d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-099856
- JSON: https://secwatch.observer/filing/0001104659-23-099856.json
- Plain text: https://secwatch.observer/filing/0001104659-23-099856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.